Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 209299
Company: RIGEL PHARMS INC

Products on NDA 209299

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
TAVALISSE	FOSTAMATINIB DISODIUM	EQ 100MG BASE	TABLET;ORAL	Prescription	None	Yes	No
TAVALISSE	FOSTAMATINIB DISODIUM	EQ 150MG BASE	TABLET;ORAL	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 209299

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
04/17/2018	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/209299Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209299Orig1s000TOC.cfm

Labels for NDA 209299

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/17/2018	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf